◀ Back to CCL2
CCL2 — CX3CL1
Text-mined interactions from Literome
Bjerkeli et al., Rheumatology (Oxford) 2007
(Wegener Granulomatosis) :
In eight of these individuals, we also examined CX3CR1 mediated chemotaxis and adhesion in T cells and monocytes as well as the
effects of
CX3CL1 on
monocyte chemoattractant protein (MCP) 1 levels in PBMC supernatants ... Our main findings were : ( i ) WG patients had markedly increased plasma levels of CX3CL1, with particularly high levels in those with active disease, ( ii ) These increased CX3CL1 levels were accompanied by enhanced expression of its corresponding receptor, CX3XR1, in PBMC, primarily reflecting an increased proportion of CX3CR1 ( + ) CD3 ( + ) CD4 ( + ) T cells and ( iii ) The up-regulation of CX3CR1 in PBMC from WG patients affected their functional potential as shown by
CX3CL1 induced enhancement of chemotaxis, adhesion, responses as well as
MCP-1 stimulation
Popovic et al., J Leukoc Biol 2008
:
Upon cocultivation of human monocytes with HUVEC, the thrombin dependent induction of membrane anchored
CX3CL1 in HUVEC
triggered monocyte adhesion and an enhanced release of the
MCP-1/CCL2 by monocytes and potentiated the monocyte transendothelial migration
Escher et al., Heart 2011
(Enterovirus Infections...) :
The
MCP-1 secretion was 3.1-fold higher in PBMCs from EV-positive patients compared with controls, and this elevation was further
increased by
CX3CL1 in EV-positive patients